about
Oncolytic herpes simplex virus vectors for cancer virotherapyFlip-Flop HSV-BAC: bacterial artificial chromosome based system for rapid generation of recombinant herpes simplex virus vectors using two independent site-specific recombinases.Directed evolution of adeno-associated virus for glioma cell transductionIdentification of the ENT1 antagonists dipyridamole and dilazep as amplifiers of oncolytic herpes simplex virus-1 replicationHypoxia enhances the replication of oncolytic herpes simplex virusAttenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation in miceTreatment of orthotopic malignant peripheral nerve sheath tumors with oncolytic herpes simplex virus.Oncolytic herpes simplex virus vectors and chemotherapy: are combinatorial strategies more effective for cancer?Current status of gene therapy for brain tumors.Treatment of human hepatocellular carcinoma by the oncolytic herpes simplex virus G47deltaReplication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma.A novel oncolytic herpes simplex virus that synergizes with phosphoinositide 3-kinase/Akt pathway inhibitors to target glioblastoma stem cells.Distinguishing inflammation from tumor and peritumoral edema by myeloperoxidase magnetic resonance imaging.Oncolytic herpes simplex virus armed with xenogeneic homologue of prostatic acid phosphatase enhances antitumor efficacy in prostate cancer.Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells.Bevacizumab with angiostatin-armed oHSV increases antiangiogenesis and decreases bevacizumab-induced invasion in U87 glioma.Maintenance of primary tumor phenotype and genotype in glioblastoma stem cells.Targeting Hypoxia-Inducible Factor 1α in a New Orthotopic Model of Glioblastoma Recapitulating the Hypoxic Tumor Microenvironment.Effect of γ34.5 deletions on oncolytic herpes simplex virus activity in brain tumors.Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing.Designing Herpes Viruses as Oncolytics.Viral vectors as therapeutic agents for glioblastoma.Multimechanistic tumor targeted oncolytic virus overcomes resistance in brain tumorsEXPLORING THE ANTITUMOR EFFECT OF VIRUS IN MALIGNANT GLIOMASingle agent efficacy of the VEGFR kinase inhibitor axitinib in preclinical models of glioblastomaCombinatorial strategies for oncolytic herpes simplex virus therapy of brain tumors.Oncolytic herpes simplex virus counteracts the hypoxia-induced modulation of glioblastoma stem-like cells.Oncolytic herpes simplex virus therapy for peripheral nerve tumors.Transient fasting enhances replication of oncolytic herpes simplex virus in glioblastoma.Combination of oncolytic herpes simplex viruses armed with angiostatin and IL-12 enhances antitumor efficacy in human glioblastoma models.Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model.Ras signaling influences permissiveness of malignant peripheral nerve sheath tumor cells to oncolytic herpesHuman glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectorsExpression of FMS-like tyrosine kinase 3 ligand by oncolytic herpes simplex virus type I prolongs survival in mice bearing established syngeneic intracranial malignant glioma.In vitro bypass of UV-induced lesions by Escherichia coli DNA polymerase I: specificity of nucleotide incorporation.Nucleoprotein complex formed between herpes simplex virus UL9 protein and the origin of DNA replication: inter- and intramolecular interactionsOncolytic viruses and their application to cancer immunotherapyBlockade of transforming growth factor-β signaling enhances oncolytic herpes simplex virus efficacy in patient-derived recurrent glioblastoma models.Treatment of human thyroid carcinoma cells with the g47delta oncolytic herpes simplex virus.Oncolytic herpes simplex virus interactions with the host immune system.
P50
Q28202611-9E5AB037-8AF2-45F3-A32D-1853EDBC14C1Q30826113-D786007B-2A59-47E9-A3C2-6A8E2B3F4D9CQ33484220-69E1C7BF-9CF3-4CA2-B5EF-95743929ECDCQ33566587-A9143709-3BD8-4C51-A01E-4D39FF53B4FAQ33660631-FCC1E54E-C50D-415F-921C-FBA04E715CB9Q33802747-88FD3E7B-1333-402B-ABEF-600EFF208A29Q33894449-DC0DBAEF-9070-4BDC-9763-AA4178BD104AQ33995471-2EB935B6-3A52-403E-AF07-E2268A68A663Q34318157-E5B2D197-F122-4932-B7E1-FF9F969B1FBAQ34423157-9A54AB8F-B226-40BB-87D8-1B7B8C281BD4Q34786262-D4798C34-E67F-4FF0-BDA9-1ECF8EB49AABQ35023915-A627AA63-8D43-45E5-9242-0A8B8F4144FAQ35091322-A6975592-2A7F-4E75-BD11-95D6DAE764A4Q35625500-357E57D6-280F-49CA-96D0-0268BAF9BE01Q35648484-918C52A2-ADBF-43AD-B317-A6AB428E8342Q35665220-F1577565-ECF1-4520-9440-E8CE3984B256Q35696355-54C8F98F-CDA0-43AC-AF7B-02AE3957D230Q35759208-888E0D89-713F-49F2-920D-95A8CCA69B63Q35867997-97664007-6D1B-4D66-9C1B-D527AC96B8FFQ35945465-CB59B778-39B9-4934-8147-7917EDDA5285Q36142487-388079EB-1881-408B-BA20-51B2FF85C4ABQ36296485-4E632B3A-0991-4894-A17B-945A7657DCEFQ36512525-6144BA59-28AF-45E8-BE7C-43B1F08FF52FQ36549443-080E4F93-2332-4E8A-9EDD-5AD42AD802F1Q36575238-426F134A-9EF6-45D9-95F5-CB6FAFA9BAD1Q36849213-8B7FC5AE-DE62-40E3-B06A-6E0B86939E9AQ36861550-A1195285-37CF-4BBA-91CD-7B4401465B28Q36871264-FD1E60D0-8208-477E-B10D-2C2F16F82904Q36878711-82F20E5F-7503-4451-A7D7-137A7D9A510AQ36879211-A812AFBD-7C31-430B-81CB-2EEC0D092EF6Q37031739-963103AB-A7EE-4163-AEC8-01A8629BEF49Q37061120-3DECC110-B870-450E-9F5B-A354F5FA828AQ37447217-B50AFB91-B899-4350-B747-F85C959A9AE2Q37579001-7DC38031-06EF-4924-8164-5DDE5E3AADB8Q37606106-0EA5C27B-544B-4F06-99D7-459F2D99DB06Q37638624-E2146E96-5C77-4E38-8D5C-739A27A942EEQ38207011-678BBD0B-27C9-45E4-8B13-A445933CE5AFQ38400073-73BFC081-B216-4285-91EC-A4337B64B4DDQ38904240-CABC9D1B-08B6-4EAF-983E-2B80A38BE030Q38920459-A3502511-FC29-4013-A51E-D593159E06DE
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Samuel D Rabkin
@ast
Samuel D Rabkin
@en
Samuel D Rabkin
@es
Samuel D Rabkin
@nl
type
label
Samuel D Rabkin
@ast
Samuel D Rabkin
@en
Samuel D Rabkin
@es
Samuel D Rabkin
@nl
prefLabel
Samuel D Rabkin
@ast
Samuel D Rabkin
@en
Samuel D Rabkin
@es
Samuel D Rabkin
@nl
P108
P106
P108
P21
P31
P496
0000-0003-2344-2795